Insights
Calvert Issue Brief: Opioids

Featured

 

Filter All Insights

Use the form below to filter insights by Topic Category or Content Type.

Topic Category

Content Type

Affiliate

Filter Insights by Date:     or  Show recent results
The article below is presented as a single post. Click here to view all posts.

By Laura AhmadiESG Research Analyst, Calvert Research and Management

This issue brief is update of Calvert’s views on the risks that opioid exposure presents to the pharmaceutical industry. In addition to updated data, it features a new section on COVID-19’s impact and the potential for it to create a “second wave” of the opioid epidemic.

The views expressed in these posts are those of the authors and are current only through the date stated. These views are subject to change at any time based upon market or other conditions, and Eaton Vance disclaims any responsibility to update such views. These views may not be relied upon as investment advice and, because investment decisions for Eaton Vance are based on many factors, may not be relied upon as an indication of trading intent on behalf of any Eaton Vance strategy. The discussion herein is general in nature and is provided for informational purposes only. There is no guarantee as to its accuracy or completeness.